A growing trend observed in pediatric sleep clinics across the nation is the frequent use of melatonin by children, either currently or at some point in their past. While melatonin is recognized as a valuable therapeutic agent for sleep disorders in pediatric populations and is often perceived as safe due to its natural origin, concerns are mounting regarding its escalating and sometimes unsupervised administration. This widespread adoption, amplified by aggressive marketing and the perception of it being a simple solution, warrants a closer examination of its efficacy, safety, and appropriate application.
The precise prevalence of melatonin use among children remains difficult to quantify definitively. However, available data offers a glimpse into its increasing consumption. A 2022 study published in JAMA estimated that adult melatonin use had tripled between 2005 and 2018, with users opting for higher doses. This trend appears to be mirrored in pediatric contexts, with aggressive marketing campaigns for children’s melatonin products contributing to its accessibility. This has led to a concerning reliance on melatonin as a perceived shortcut to addressing sleep challenges, potentially at the expense of establishing robust sleep hygiene practices. Anecdotal evidence, such as a father’s review on Amazon quoted in a Wall Street Journal article, highlights this phenomenon: "OK, yes, as parents my wife and I should do a better job starting the bedtime routine earlier, turning off the TV earlier, limiting sweets, etc., etc. Well, for whatever reason, this is not our strong suit. This 1 mg light dosage of melatonin is very helpful winding our kids down and getting them ready for bed." This sentiment underscores the convenience factor that may be driving parental decisions.
Further underscoring the rising consumption, a New York Times article from May 2020, titled "Parents Are Relying on Melatonin to Help Their Kids Sleep. Should They?", reported an 87% increase in overall melatonin sales in the year preceding March 2020. A survey conducted by the Times involving 933 parents of children under 18 revealed that over half of these parents had administered melatonin to their children at some point. More recent global data paints an even more striking picture. Scandinavia has witnessed an almost 500% surge in melatonin prescriptions. In the United States, melatonin has become the most common cause of overdose incidents in pediatric emergency rooms and a frequent reason for calls to poison control centers, indicating a significant and potentially escalating public health issue.
Understanding Melatonin’s Role in Sleep
Melatonin is a hormone naturally produced by the pineal gland in the brain. It functions as a chronobiotic agent, regulating the body’s circadian rhythm or internal clock, and at higher concentrations, it can act as a hypnotic, inducing sleep. Crucially, while its hypnotic effect is not universal, its chronobiotic influence is present in all individuals. The natural increase in melatonin levels one to three hours before sleep onset, known as the "dim light melatonin onset" (DLMO), signals the body’s readiness for sleep and marks the end of the brain’s wakefulness signal. For children experiencing insomnia, particularly those whose natural DLMO occurs later than their designated bedtime, melatonin administration might be considered. In such cases, it essentially attempts to align the body’s internal clock with the desired sleep schedule. Clinical doses, often ranging from 0.5 mg to 10 mg or higher, significantly exceed the physiological amounts secreted naturally by the body.
Effectiveness of Melatonin for Pediatric Sleep Issues
The documented benefits of melatonin for children include a reduction in the time it takes to fall asleep and an increase in overall sleep duration. However, the scientific evidence supporting its efficacy, particularly for long-term use in children, is still developing. Studies are often characterized by small sample sizes and short follow-up periods. A significant factor contributing to this data gap is that melatonin is regulated as a dietary supplement by the U.S. Food and Drug Administration (FDA), rather than as a pharmaceutical. This regulatory classification means that large-scale, long-term safety and efficacy trials, typically funded by pharmaceutical companies for prescription drugs, are less common for melatonin. The International Pediatric Sleep Association (IPSA) provides valuable resources, including parent guides and literature reviews, which offer insights into melatonin’s use in both typically developing children and those with autism.
The overarching consensus from current research suggests that melatonin can contribute to approximately 30 minutes of additional sleep per night, primarily by shortening the sleep onset latency. While this benefit is consistent across studies, it is important to emphasize that melatonin is not a panacea for all sleep-related problems.
Chronic Sleep Onset Insomnia in Typically Developing Children
Difficulty falling asleep is a prevalent issue among children, mirroring adult experiences. Chronic insomnia is diagnosed when sleep onset or maintenance difficulties occur at least three times per week for three months or more, leading to dissatisfaction with sleep or observable daytime impairments. A 2023 meta-analysis by Edemann-Callesen, which synthesized data from 419 children, indicated an approximate 30-minute increase in overnight sleep, with about 18 minutes attributed to a reduction in sleep latency. Notably, this study found no improvement in daytime functioning and observed an increase in adverse events in the group receiving melatonin compared to the placebo group. The 2025 IPSA position paper on melatonin for typically developing children offers important recommendations, emphasizing a cautious approach and prioritizing behavioral interventions.
Autism Spectrum Disorder (ASD) and Melatonin
Sleep disturbances are particularly common in children with Autism Spectrum Disorder (ASD), manifesting as prolonged sleep onset, reduced nighttime sleep, and issues with waking during the night or early morning. Some research suggests that children with ASD may have lower melatonin levels and less variation in their daily melatonin secretion. Consequently, melatonin has been frequently used in this population, often leading to improvements in falling asleep and increased total sleep time. Studies have explored both immediate-release and extended-release formulations, typically administering melatonin 30-60 minutes before bedtime.
A 2025 meta-analysis by Yang et al. identified sleep efficiency and total sleep time as the primary areas of benefit, rather than sleep latency. The study indicated that the effectiveness of melatonin was more pronounced in older children. While the benefits of melatonin can diminish over time, higher doses appeared more effective than lower ones. A 2017 trial involving a time-released melatonin preparation (PedPRM) demonstrated significant improvements, with children sleeping an average of 57.5 minutes longer compared to a control group. This benefit was largely attributed to a reduction in the time taken to fall asleep. While this particular medication is available in Europe, its approval by the FDA in the U.S. remains uncertain. The 2024 IPSA recommendations for melatonin use in ASD highlight the importance of integrating melatonin into a comprehensive behavioral management plan, recommending its use only after behavioral interventions have proven insufficient. Established resources for families, such as the Autism Speaks Sleep Toolkit and the book "Solving Sleep Problems in Children with Autism Spectrum Disorders: A Guide for Frazzled Families," provide further guidance.
Attention-Deficit/Hyperactivity Disorder (ADHD) and Melatonin
A significant correlation exists between Attention-Deficit/Hyperactivity Disorder (ADHD) and sleep problems, with as many as 70% of children with ADHD experiencing sleep disturbances. These issues can range from difficulty falling asleep to altered sleep architecture and daytime sleepiness. A 2024 review by Cortese on managing sleep issues in ADHD noted two randomized controlled trials demonstrating positive effects. A systematic review by Larsson in 2024 reported a 30-minute decrease in sleep latency and improved sleep efficiency, but found no evidence of improvement in quality of life or daytime ADHD symptoms. While one small trial suggested melatonin could aid children with ADHD on stimulant medication, this was based on chart review. The American Academy of Neurology guidelines recommend addressing behavioral issues first, followed by short-acting melatonin, and then potentially extended-release formulations.
Delayed Sleep Phase Syndrome (DSPS) and Melatonin
Delayed Sleep Phase Syndrome (DSPS) is a common disorder among adolescents, characterized by a significant shift in their natural sleep-wake cycle, making it difficult to fall asleep at socially conventional times. Teens with DSPS often struggle to fall asleep until the early morning hours, frequently between 1-2 AM or even later. Melatonin plays a crucial role in managing DSPS. Administering small doses several hours before the desired sleep onset, in conjunction with light exposure management, sleep hygiene, and gradual schedule adjustments, can be effective. The underlying issue in DSPS is a delayed DLMO, and melatonin can help advance the sleep period. For children with DSPS, a recommended approach involves administering a dose 4-6 hours prior to their current sleep onset time, gradually advancing it every 4-5 days, using low-dose preparations. Among the conditions discussed, DSPS appears to have the most clearly defined and significant benefit from melatonin.
Other Pediatric Conditions and Melatonin
Children with various forms of neurodevelopmental delay may also experience significant insomnia, and melatonin might offer some relief. However, in some cases, its use has been associated with persistently elevated daytime melatonin levels and subsequent daytime sleepiness. A 2023 review by Edemann-Callesen examined melatonin’s effects across a range of conditions, including atopic dermatitis, epilepsy, and various genetic disorders. While total sleep time increased by approximately 19 minutes (largely due to reduced latency), there was no evidence of subjective sleep improvement or daytime functional gains.
Limited research exists regarding melatonin’s efficacy in children with blindness who may experience sleep-wake cycle disruptions due to the absence of light cues for their circadian rhythm. Small trials in adults have shown some benefit, but the data for pediatric populations remains very limited.
Eczema, characterized by dry, itchy skin, is often associated with sleep disturbances and non-restorative sleep in children. Some studies suggest that children with eczema may have lower melatonin levels, and preliminary research indicates that melatonin supplementation could be beneficial.
Concerns Regarding Melatonin Use in Children
Despite its widespread use and natural origin, several concerns warrant careful consideration regarding melatonin administration in children. These include theoretical side effects, potential issues with product quality and labeling, and the adequacy of long-term safety data.
Theoretical Side Effects: A primary concern is the potential for persistently elevated blood melatonin levels throughout the day, which could lead to daytime sleepiness. However, the full spectrum of other potential long-term effects remains unclear. It is critical to acknowledge that melatonin has not undergone the same rigorous testing as pharmaceutical drugs due to its classification as a dietary supplement. Long-term studies often rely heavily on parental reports rather than biochemical measurements. Dr. David Kennaway, a physician from Australia, has published editorials highlighting the inadequacy of existing long-term safety data for children, notably stating, "…parents should always be informed that (1) melatonin is not registered for use in children, (2) no rigorous long-term safety studies have been conducted in children and by the way (3) melatonin is also a registered veterinary drug used to alter the reproduction of sheep and goats." This perspective underscores the need for greater caution and informed consent.
Product Quality and Labeling Issues: The regulatory oversight for dietary supplements is substantially less stringent than for pharmaceuticals, leading to potential variations in safety and efficacy. Furthermore, the labeling of many melatonin preparations can be misleading. For example, a liquid preparation marketed as "1 mg" might actually contain only 0.25 mg per dropperful, with the accurate dosage information relegated to the package insert, which is often overlooked by consumers. This ambiguity can lead to accidental under- or over-dosing.
Reassuring Long-Term Safety Data: A 2020 study that followed 80 children using a specific extended-release melatonin formulation (PedPRM) for two years reported no evidence of adverse effects on weight, height, body mass index, or sexual development. While this study offers some reassurance regarding the safety of this particular preparation, the broader need for more extensive long-term safety studies across various melatonin products remains.
Parental and Physician Considerations
For parents whose children are already taking melatonin, a calm and informed approach is recommended. If melatonin was initiated without physician consultation, it is strongly advised to discuss its necessity with the child’s pediatrician. For children on long-term melatonin therapy who are sleeping well, a gradual dose reduction or intermittent use ("as needed" rather than nightly) can be considered. A thorough review of sleep hygiene practices, including establishing a consistent and high-quality bedtime routine and limiting screen time before bed, is paramount. Periodic trials off melatonin, as recommended by IPSA guidelines (limiting use to 3-6 months and then attempting discontinuation), are also advised. Maintaining safe storage of melatonin and ensuring appropriate dosing are critical to prevent accidental ingestion or overdose.
When melatonin is prescribed by a physician, careful consideration of timing and dosage is essential. The effectiveness of melatonin can vary significantly based on when it is administered relative to the child’s usual sleep schedule. A small dose given a few hours before bedtime may be more effective than a larger dose at bedtime. Generally, administering melatonin 30-60 minutes prior to bedtime is considered optimal, though earlier administration may be beneficial in some cases.
Dosage Recommendations: The 2025 IPSA guidelines provide age-based dosing ceilings. It is recommended to start at a low dose of 0.5 mg and increase weekly by 0.5 mg until improvement is observed or the maximum dose for the child’s age group is reached. A direct link to the IPSA parental information sheet in English is available for detailed guidance. A melatonin dosing calculator has also been developed to assist parents in selecting the safest dose for their child based on the latest guidelines.
Crucially, melatonin should never be viewed as a substitute for good sleep hygiene practices. It should always be used in conjunction with a high-quality bedtime routine, appropriate limitations on light exposure, and a consistent sleep schedule. When possible, choosing a USP Verified preparation may indicate adherence to stricter quality control standards set by the U.S. Pharmacopeial Convention.
Conclusion: The Take-Home Message
Decisions regarding the use of melatonin in children are often made after considerable deliberation and typically follow unsuccessful attempts to address sleep problems through behavioral interventions. The limited availability of FDA-approved insomnia medications for children (with chloral hydrate being largely unavailable) further complicates treatment options. While concerns about the long-term safety and efficacy of melatonin are valid, its potential to significantly improve sleep for certain children and families is undeniable. Pediatricians often utilize melatonin in their practice, recognizing the profound impact of poor sleep on children and their families. The primary goal remains to achieve adequate sleep with minimal reliance on medication, investigating and addressing any underlying causes of insomnia, such as restless leg syndrome. For some children, particularly those with autism or developmental challenges, melatonin may be a necessary component of a comprehensive sleep management plan. It may be a suitable option for a child if:
- Behavioral interventions and sleep hygiene have been thoroughly implemented and have proven insufficient.
- The child has a diagnosed sleep disorder for which melatonin is indicated, such as Delayed Sleep Phase Syndrome or specific forms of insomnia associated with neurodevelopmental conditions.
- The potential benefits of improved sleep are deemed to outweigh the identified risks, under the guidance of a healthcare professional.
In instances where sleep difficulties emerge unexpectedly, it is important to consider the possibility of a sleep regression and consult resources for managing such periods.
A special acknowledgment is extended to Bob Young R.Ph for his contributions to the initial development of this article.
Originally published April 2026. Last reviewed/updated by Dr. Craig Canapari, MD in April 2026
